Cytek Biosciences, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter report; the provided filing text does not give clear Q4-only financial results. Cytek develops and sells cell-analysis instruments, reagents, software and services, led by its Aurora and Northern Lights flow cytometers. Its shares began trading on Nasdaq in July 2021 (CTKB).
Key financial results
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $128.0 million | $92.8 million | Up 38% |
| Gross profit / margin | $79.1 million / 62% | $51.7 million / 56% | Margin up 6 percentage points |
| Operating expenses | $70.0 million | $38.1 million | Up 84% |
| Income from operations | $9.2 million | $13.7 million | Down 33% |
| Net income | $3.0 million | $19.4 million | Down 84% |
| Cash from operating activities | $4.6 million | $15.2 million | Down $10.5 million |
- Product revenue was $119.5 million, up 40%, primarily from higher Aurora and Northern Lights sales, the June 2021 launch of Aurora CS, and product mix. Service revenue rose 12% to $8.4 million.
- Product gross margin increased to 69% from 62%. Service gross margin remained negative and declined to (36)% from (17)%, reflecting higher service staffing costs and reduced non-Cytek service-contract revenue.
- Cash and cash equivalents were $364.6 million at year-end, versus $165.2 million a year earlier. Current assets were $431.7 million and current liabilities $33.2 million. Total liabilities were $57.9 million, including a $15.2 million BD settlement liability. The $4.1 million PPP loan was fully repaid in May 2021; the filing reports no other borrowings in the presented balance sheet.
- Investing cash outflow was $21.0 million, including $17.0 million for the Tonbo reagents-business acquisition and $4.4 million in property and equipment purchases. Financing cash inflow was $213.6 million, principally from $215.7 million in net IPO proceeds.
Material changes and notable items
- Revenue growth did not translate into higher operating or net income: operating expenses rose to $70.0 million, with R&D up 78% to $24.4 million, sales and marketing up 65% to $24.7 million, and general and administrative expense up 122% to $20.8 million. Increases reflected hiring, growth investment, IPO-related professional fees and public-company costs.
- The year-over-year net-income comparison was affected by a $5.0 million income-tax benefit in 2020, including an $8.1 million U.S. valuation-allowance release, versus a $2.9 million tax provision in 2021. Foreign-exchange results also shifted from $1.0 million of other income to $1.5 million of other expense.
- Cytek acquired Tonbo’s reagents business for $17.0 million in November 2021, including $9.7 million of goodwill and $4.7 million of identifiable intangible assets. The acquired business’s revenue and operating loss were not material in the reported period.
- In 2021, the company shipped 1,110 cumulative instruments. Direct sales accounted for 86% of revenue, compared with 83% in 2020. Academic and government customers represented 46% of revenue, down from 49%.
- Under the 2020 BD settlement, Cytek owes low-single-digit royalties on certain products for ten years and a $6.0 million milestone upon reaching a sales threshold; the filing says the threshold was achieved by year-end 2021. The settlement liability was $15.2 million at year-end.
Outlook, risks and controls
- No numerical revenue or earnings guidance is provided. Management expects expenses to increase as it hires, invests in R&D and commercial infrastructure, expands internationally and supports new products. It expects cash and anticipated operating cash flows to meet working-capital and capital-expenditure needs for at least 12 months from the filing date.
- Management expects recurring reagent and service revenue to become more important as the installed base grows, and sees clinical markets as an expansion opportunity. U.S. instruments are principally marketed for research use; clinical use there may require FDA clearance or approval. Northern Lights has clinical certifications in the EU and China.
- Key risks include reliance on a limited set of instrument products and single- or limited-source suppliers; long, potentially fluctuating sales cycles; competition and adoption uncertainty; dependence on academic and government research funding; regulatory hurdles; international and currency exposure; and COVID-19-related uncertainty. Management reported no material COVID-19 impact to date and no material supply issues, but said future effects could not be reliably estimated.
- Disclosure controls were deemed ineffective as of December 31, 2021 because of previously identified material weaknesses involving qualified accounting and IT personnel, GAAP policies and procedures, and IT and financial-reporting controls. Management described remediation efforts, but the auditor did not attest to internal-control effectiveness. The financial-statement audit opinion was unqualified.
- Cytek reported no material pending legal proceedings. It had approximately $1.8 million accrued for product warranties. The filing also notes that the company does not maintain separate environmental-liability insurance.
Important facts for investors to verify
- Whether instrument demand, installed-base growth and reagent pull-through sustain revenue growth, and whether service margins improve.
- Whether expense growth moderates enough to restore operating-income and net-income growth; distinguish consolidated net income from income attributable to common stockholders, which was reported as zero in 2021 under the two-class allocation.
- The cash-flow effect of receivables, inventory and prepaid assets, which increased in 2021, and the company’s planned capital spending and cash runway.
- The eventual accounting and cash-payment effects of the achieved BD milestone, continuing royalties and any change-of-control payment.
- Progress in remediating material weaknesses and the results of required future internal-control assessments.
- Tonbo’s contribution to revenue and profitability, and the assumptions supporting its goodwill and intangible-asset valuations.